Yescarta

Representative image: Gilead Sciences’ HIV drug growth helped lift its Q1 performance, highlighting how Biktarvy, Descovy and long-acting prevention therapies remain central to the company’s biopharma growth story.

Gilead’s Q1 shows HIV momentum remains powerful, but diversification is still unfinished

by Pallavi Madhiraju
May 9, 2026
0 Comments

Gilead’s HIV engine is roaring again. But acquisition costs and oncology pressure leave investors asking how durable the reset really is.

$Representative image: Illustration depicting CAR T-cell therapy research in the central nervous system, reflecting the FDA’s removal of Yescarta’s CNS limitation for relapsed or refractory primary CNS lymphoma.$

Pharma & Biotech

FDA removes CNS limitation for Yescarta, reshaping the regulatory boundary for CAR T therapy in primary CNS lymphoma

by Pallavi Madhiraju
February 9, 2026
0 Comments

Kite Pharma, a subsidiary of Gilead Sciences, has received approval from the U.S. Food and Drug Administration to update the prescribing information for Yescarta axicabtagene ciloleucel by removing the prior limitation of use in patients with relapsed or refractory primary central nervous system lymphoma. The decision follows safety findings from an investigator sponsored Phase 1